The Pharmaceutical Journal
Vol 270 No 7251 p742
31 May 2003

This article
Reprint
Photocopy

News summary

Conference summaries  24 May   31 May  

Related websites
American Thoracic Society conference 2003 (more)

Linezolid for resistant TB

Five patients with tuberculosis resistant to between eight and 14 therapies benefited from receiving linezolid (Zyvox). Addition of linezolid to their failing drug therapy led to sustained negative conversion of sputum cultures in all patients. "This certainly seems like a promising medication for drug-resistant TB," said Dr Timothy Harkin, assistant director of Bellevue Hospital's chest service, New York. Dr Harkin hopes that linezolid will be the subject of clinical trials sponsored by the World Health Organization.

The Journal attended the American Thoracic Society's 99th international conference in Seattle, Washington, courtesy of GlaxoSmithKline